Kornimate/medical-research-clean huggingface dataset:
effect of intensive low sodium restriction on glomerular infiltration rate in chronic kidney disease

Conditions: Declination of Glomerular Infiltration Rate in Chronic Kidney Disease Population

Summary: introduction : due to chronic kidney disease is a public health problem, which is important increased in both developed and developing countries . and sodium intake restriction was related to the reduction of blood pressure and urine protein which is one of the important risk factor in chronic kidney disease. one of the problem in sodium restriction failure in thai population with ckd nowadays is lack of knowledge and problem unawareness. the study hypothesis : intense knowledge about sodium reduction and immediate feedback of the sodium intake could be simultaneously modifying the behavior to reduce sodium intake , blood pressure and also gfr reduction rate objectives : to compare the effect of dietary salt restriction on glomerular filtration rate (gfr) between ckd patients receiving strict controlled combined with immediate individual feedback (disc progrram) and those receiving standard education. study design : multicenter, open labeled, parallel, randomized controlled trial sample size : 600 primary outcome : gfr reduction (ckd-epi) secondary outcome : * achievement rate of na intake \< 2 g/day (urine na \< 90 meq/day) * blood pressure difference * proportions of patients with bp reached the target (130/80 mmhg) * number of anti-hypertensive drugs use to achieve bp target * urine albumin/creatinine ratio * major adverse cardiac events (mace) * cardio-ankle vascular index (cavi) * ankle-brachial index (abi) documentary proof of ethical clearance : this project has been reviewed and approved by the comittee on human rights related to research involving human subjects , based on the declaration of helsinki


Eligibility criteria:
inclusion criteria: * ckd stage 3-4 (egfr 15-59 ml/min/1.73m²) * microalbuminuria * any blood pressure level exclusion criteria: * salt - losing conditions * hyponatremia (na \ 145 mg/dl) * bilateral renal artery stenosis * severe comorbid disease or life expectancy \<1 year (severe cardiovascular disease, chronic liver disease, severe infection , malignancy) * immunosuppressant used
penn medicine healthy heart

Conditions: Hypertension; Hyperlipidemias

Summary: to leverage access to patients across the primary care network, epic tools for identifying eligible patients, and the way to health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for penn medicine patients in west/southwest philadelphia and lancaster.

to leverage access to patients across the primary care network, epic tools for identifying eligible patients, and the way to health platform to launch and enroll penn medicine primary care patients into the penn medicine healthy heart, a six-month program for reduction of hypertension and hypercholesterolemia grounded in behavioral economics insights to increase uptake of and adherence to evidence-based interventions to reduce ascvd risk. penn medicine healthy heart emphasizes proactive outreach and prevention outside of a traditional visit model using data assets to identify and risk stratify patients. the program aims to relieve overburdened pcps through automated hovering technology coupled with a centralized, leveraged team of non-clinical navigators and nurse practitioners. the clinical trial will assess penn medicine healthy heart and will be powered to detect differences in improving blood pressure and cholesterol over 6 months for penn medicine patients in west/southwest/downtown philadelphia and lancaster, pa.

Eligibility criteria:
inclusion criteria: * on the penn medicine primary care service line registry * last 2 blood pressure readings with systolic blood pressure \>=140 from any outpatient encounter in the last 12 months and * ascvd dx or ascvd risk score ≥10% or diabetes dx or a1c ≥6.5 in last year or diabetes registry or last ldl ≥190 in past five years and * not on a statinor pcsk9, inclisiran or on a low-intensity/moderate-intensity statin) with ldl \>100 exclusion criteria: * patients on pcsk9 inhibitors * documented statin allergy/ or intolerance in the emr * pregnancy * breast feeding * markedly shortened life expectancy including: 1. metastatic cancer 2. hospice 3. end stage renal disease 4. congestive heart failure 5. dementia * is a non-english speaker requiring a translator * patients who do not have a cell phone
comparison of the effectiveness of different home exercise programs

Conditions: Cognitive Function 1, Social

Summary: aging is defined as a functional change in the organism which is not reversible with time progression. with this change in the organism, physical and cognitive functions are decreasing, and the potential of the individual to establish a balance between the systems decreased. for this reason, the aim of this is to investigate the effects of different home exercise programs on cognitive function, balance and daily living activities in healthy individuals.

40 healthy individuals between the ages of 60-80 who agreed to participate in the study will be included in the study. participants will be divided into 2 groups randomly. both groups will be given balance exercises with aerobic exercise. the second group will be given second additional cognitive task besides doing usual exercises that the first group is performing. exercises will be given in the form of a home exercise program and the treatment will last for 6 weeks. the continuity of the exercises will be controlled by telerehabilitation method. the participants will be evaluated before and after the treatment.

Eligibility criteria:
inclusion criteria: * participants between the ages of 60 and 80 * mini mental status test score to be over 24 exclusion criteria: * cardiovascular disease * cardiovascular surgery operation, pacemaker etc.

Keywords: balance cognitive function healthy individuals quality of life cognitive exercises depression
ancillary study to protocol 20060104

Conditions: Rheumatoid Arthritis

Summary: ancillary study to the etanercept protocol 20060104. subjects have been asked to provide additional blood samples for further assessment.


Eligibility criteria:
inclusion criteria: * signed informed consent meet all inclusion critieria outlined in amgen protocol 20060104 exclusion criteria: * meet exclusion criteria outlined in amgen protocol 20060104

Keywords: rheumatoid arthritis etanercept enbrel amgen
an ergonomic training with exercise program for work-related musculoskeletal disorders among hemodialysis nurse

Conditions: Musculoskeletal Disorders

Summary: this study aimed to examine the effectiveness of the 12-week ergonomic intervention developed by person-environment-occupation (peo) model in improving musculoskeletal discomfort and muscle strength for hemodialysis nurses. the maintenance effects of the intervention were also evaluated after another 12-week follow-up.

methods a cluster experimental design was used to conduct this study. participants were recruited from hemodialysis units at two medical centers in taiwan and had complaints of work-related musculoskeletal disorders (wmsds) within the past six months. by peo model, the 12-week intervention including ergonomic education and exercise program was designed based on the job contents of hemodialysis nurses. in the study period, we used a mobile massager app to reminder them and monitor their implementation of exercises. the outcome indicators were measured before and after intervention as well as the follow-up after another 12 weeks. a generalized estimating equations model was adopted to analyze the repeated measurements.

Eligibility criteria:
inclusion criteria: * 20 to 65 years old, which is the legal age range of adult for work in taiwan * registered nurses to work full time in the hemodialysis unit more than 6 months, * having complaint of wmsds within previous 6 months before this study. exclusion criteria: * having no musculoskeletal disorder related to the job * to care less than 4 patients in 4 hours, which was below the taiwan workload reference for nurse in hemodialysis job * to have any other consideration to keep from 12- week physical exercise program (such as pregnancy, injury, disease, leave..., etc.).
a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of rag-17 in subjects with amyotrophic lateral sclerosis (als) with superoxide dismutase type 1 (sod1) gene mutation

Conditions: Amyotrophic Lateral Sclerosis

Summary: this is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of rag-17 in subjects with amyotrophic lateral sclerosis (als) with superoxide dismutase type 1 (sod1) gene mutation

the study is a phase 1, randomized, double-blind, placebo controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of rag-17 in patients with amyotrophic lateral sclerosis (als) with superoxide dismutase type 1 (sod1) gene mutation. the dose levels will be evaluated sequentially across separate cohorts using a rules-based design, wherein participants will receive rag-17 or placebo at a ratio of 3:1.

Eligibility criteria:
inclusion criteria: 1. voluntarily consents to participate in this study and provides written informed consent prior to the start of any study specific procedures. 2. ≥ 18 years of age at the time of informed consent. 3. diagnosis of possible, laboratory supported probable, probable, or definite als according to the world federation of neurology el escorial. 4. documented sod1 mutation. 5. forced vital capacity (fvc) ≥50% of predicted value as adjusted for sex, age, and height (measured seated). 6. if taking riluzole or edaravone, subject must be on a stable dose or ≥30 days prior to day 1 and expected to remain at that dose until the final study visit. exclusion criteria: 1. documented p.f21c sod1 mutation. 2. treatment with another investigational drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed. 3. current enrollment in any other interventional study. 4. history of or positive test result for human immunodeficiency virus, hepatitis c virus antibody or hepatitis b virus. 5. pregnant or currently breastfeeding.
supervised computerized active program for people with post-covid syndrome (supercap study)

Conditions: Post-COVID Condition

Summary: supercap study is a project aimed at designing and implementing an online program for improvement of cognitive, emotional, and functional status in post-covid condition.

supercap study will include 2 stages. stage 1 will involve the composition of a focus group previous to the effectiveness study development. the work with this focus group will have several aims, among them, mainly, to participate in the design of the intervention program, and to provide feedback on the study follow-up. stage 2 will include the effectiveness study. this stage will comprise the initiation of the intervention program, study follow-up, and dissemination of the results in the end of the project. two study groups will participate: the intervention group and the control group. the intervention group will be comprised by people with post-covid condition who will follow the intervention program proposed. the control group will be comprised by people with post-covid condition who will not follow the program. both groups will fulfill the same study participation criteria. the intervention will consist of the follow-up of a distance program via mobile/tablet. this program will integrate different games and exercises always with the objective of stimulating the cognitive functioning and the emotional status.

Eligibility criteria:
inclusion criteria: * presenting post-covid syndrome, defined as presenting 3 or more symptoms associated with post-covid condition for at least 3 months. * age of 18-65 years old. * presence of self-reported cognitive complaints associated with post-covid infection. * positive and favorable attitude on the use of electronic devices. * will to participate in a stimulation program for improvement of cognitive symptoms. * availability of cell phone and computer or tablet with the minimum technical features considered. exclusion criteria: * inability to undergo the neuropsychological tests or complementary study assessments. * current participation in a trial or program for improvement of post-covid symptoms. * any condition that in the opinion of the investigator would make study participation unsafe, complicate interpretation of study outcome data, interfere with achieving the study objectives, or otherwise could impair the subject's ability to complete the study.

Keywords: long covid (lc) post-acute covid-19 syndrome (pacs) post-acute sequelae of covid-19 (pasc) post-acute sequelae of sars-cov-2 (pass) post-covid condition (pcc) post-covid syndrome (pcs)
nicotine withdrawal and reward processing: connecting neurobiology to real-world behavior

Conditions: Cigarette Smoking; Nicotine Withdrawal

Summary: this study is designed to find out how smoking affects the way the brain responds to pleasure and how this impacts smokers' behavior. participants will complete three sessions. the first session will be a screening and training visit to determine final eligibility. eligible participants will work with a researcher to develop brief scripts about times when they smoke and do other activities. next, participants will attend two magnetic resonance imaging (mri) scans - one after abstaining from smoking for 24 hours and the other after smoking as usual. after the second mri, participants will answer questions on their phone every day for two weeks.


Eligibility criteria:
inclusion criteria: * generally healthy * right-handed * smoke \>= 10 cigarettes per day * smoking regularly for \>= 1 year * carbon monoxide (co) \> 8 at screening (or urinary cotinine \> 100) * own a compatible smartphone * able to read and understand english * able to identify at least 4 pleasurable activities they do not do concurrently with smoking or associate with smoking exclusion criteria: * regular use of "roll your own" cigarettes * planning to quit smoking within the next 60 days * current or planned smoking cessation treatment * regular use of smokeless tobacco or other nicotine products * expired co \> 80 parts per million * breath alcohol \> .000 at screening (re-attempts are allowed) * positive toxicology screen for exclusionary drugs * use of exclusionary medications * significant medical problems * currently breastfeeding, pregnant, or planning to become pregnant * enrollment in another study utilizing spectrum cigarettes within the last 3 months * irregular slee-wake cycles (e.g. swing-shift work, unusual sleep patterns)
effect of colchicine on the progression of aortic valve stenosis - a pilot study

Conditions: Aortic Stenosis; Inflammation

Summary: copas pilot is a pilot single center double blinded randomized study to determine the effect of targeted anti-inflammation therapy using colchicine, on valvular calcification activity using imaging, i.e. aortic valvular naf uptake. the current proposal uses a randomized design to evaluate the effect of colchicine vs. placebo on valvular calcification activity over 6 months measured using naf pet

copas pilot is a pilot single center double blinded randomized study. the investigators will compare the effect of colchicine (0.6 mg daily - intervention arm) vs. placebo (control group) on the 18f naf aortic valve uptake in patients with mild to moderate as defined by a mean pressure gradient measured using transthoracic echocardiography (tte) between 15-25 mm hg after a 6-month period of treatment. the investigators plan to enroll 12 patients (6 males/6 females) in each arm (total sample size: 24 patients). primary endpoint is the change in 18fnaf aortic valve uptake between baseline and 6 months in each arm. parameters of interest are the maximal and total standard uptake values (suvs) and tissue-to background ratios (tbrs) at the level of the aortic valve.

Eligibility criteria:
inclusion criteria: 1. mild to moderate aortic stenosis defined by a mean pressure gradient using transthoracic echocardiography (tte) between 15-25mmhg. 2. age greater than18 years; 3. given informed consent. exclusion criteria: 1. bicuspid aortic valve 2. associated moderate to severe aortic regurgitation 3. associated other valvular pathology of moderate or greater severity 4. lv dysfunction (ef\<50%); 5. decompensated heart failure; 6. active infection (e.g. pneumonia, active skin infections, and on antibiotics); 7. chronic diarrhea; 8. immune compromise (e.g. recurrent infection); 9. history of cancer within the last 3 years (other than a successfully treated cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix). 10. active inflammatory conditions (e.g. rheumatoid arthritis, chronic inflammatory bowel disease, sle, systemic anti-inflammatory therapy (e.g. prednisone, methotrexate)); 11. pregnancy (all women of child bearing potential will have a negative bhcg test; 12. breastfeeding; 13. women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study or men capable of fathering a child who refuse to use contraception. 14. glomerular filtration rate (gfr) \<50 ml/min/1.72m2; 15. use of p-glycoprotein inhibitor (e.g. cyclosporine, verapamil, or quinidine) or a strong cyp3a4 inhibitor (e.g. ritonavir, clarithromycin, or ketoconazole); 16. hemoglobin \< 105(women) \<110 (men) g/l; wbc \< 3.0x 10(9)/l, platelet count\< 110x 10(9)/l; 17. patient with a history of cirrhosis, chronic active hepatitis or severe hepatic disease or with alanine aminotransferase (alt) levels greater than 3 times the upper limit of normal. 18. unable to give informed consent

Keywords: colchicine
primary cardiovascular risk prevention with aspirin in chronic kidney disease patients

Conditions: Chronic Kidney Disease Stage 4; Chronic Kidney Disease Stage 3

Summary: the objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).

hypothesis: the low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding

Eligibility criteria:
inclusion criteria: * sign informed consent * males 45-79 years or females 55-79 years. -stage 3 or 4 ckd (estimated gfr by mdrd abbreviated, between 15 and 60 ml / min/1.73 m2) - exclusion criteria: * a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented * hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid * coagulopathy from any cause * thrombocytopenia \<150,000 platelets * liver disease from any cause * infection by hepatitis b virus, hepatitis c or hiv * immunosuppressive treatment within 12 weeks before inclusion in the study * major bleeding events including gastrointestinal bleeding and brain hemorrhage. * hemoglobinopathies (eg sickle cell disease or thalassemia of any kind) * active malignancy (except non-melanoma skin cancer). may be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years. * uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, chrom disease or bowel inflammatory disease) * hemolysis * treatment with oral anticoagulation and / or antiplatelet therapy prior. * poorly controlled hypertension (\> 160/90 mm hg) -pregnancy or breast- * women of childbearing potential not using effective contraception.

Keywords: cardiovascular events chronic kidney disease bleedings progression antiinflammatory effects
intermittent-pneumatic compression in inhalation-injury children: effects on diaphragm mobility and pulmonary function

Conditions: Inhalation Injury

Summary: inhalation injury is very common in infants, young, children. complications of this problems are low pulmonary functions and limited mobility of main inspiratory muscle.

inhalation injury patients (children, n = 40) will be included in intermittent pneumatic compression group (n = 20, this device, intermittent pneumatic compression, will be used a resistive inspiratory muscle training for diaphragm muscle and the 10-set training will be done five session per the week, for 12 weeks. besides this training, traditional physical therapy program will be handled). in other inhalation group, n =20, traditional physical therapy program will be handled only)

Eligibility criteria:
inclusion criteria: * inhalation injury exclusion criteria: * brain injury * fractures of any body part * cardiac or chest disorders
the role of inflammation and vasodilatation in pacap38-induced headache using mri on healthy subjects

Conditions: Headache

Summary: studying pituitary adenylate cyclase-activating peptide 38 (pacap38) induced headache effects on extra- and intracerebral arteries and pre-posttreated by sumatriptan and ketorolac assessed by magnetic resonance imaging (mri) on healthy volunteers.

the purpose of this research project is to investigate the importance of blood vessel (vasodilatation), vessel wall inflammation and blood flow in arteries of headaches triggered by pacap38 and for headache treated with sumatriptan (migraine medicine) and ketorolac (nsaid). in addition, we will investigate headache-related changes in the brain's network connectivity.

Eligibility criteria:
inclusion criteria: * healthy volunteers * aged 18-50 * 50-100 kg exclusion criteria: * tension type headache more than 5 dag /month * other primary headaches * daily medication except contraceptives * drug taken within 4 times the half-life for the specific drug except contraceptives * pregnant or lactating women * exposure to radiation within the last year * headache within the last 24 hours before start of trial * hypertension * hypotension * respiratory or cardiac disease * primary relatives with current or previous migraine